Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 2/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.30 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.30 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436023 | 1.00 | KIF11 (0.34) | KIF11MEN1LMNAKMT2ADUT | |
| SCHEMBL19349124 | 0.88 | DUT (0.39) | KIF11MEN1KMT2ADUTTSHR | |
| SCHEMBL19349125 | 0.88 | DUT (0.39) | KIF11MEN1KMT2ADUTTSHR | |
| SCHEMBL8893033 | 0.83 | CYP1A2 (0.37) | KMT2AFOLH1TSHR | |
| SCHEMBL8892535 | 0.83 | CYP1A2 (0.37) | KMT2AFOLH1TSHR | |
| SCHEMBL25182246 | 0.80 | PRSS1 (0.37) | LMNAKMT2AALDH1A1 | |
| SCHEMBL4738904 | 0.80 | EPOR (0.42) | MDM2TSHR | |
| SCHEMBL5548812 | 0.80 | EPOR (0.42) | MDM2TSHR | |
| SCHEMBL25178739 | 0.79 | FFAR1 (0.36) | MEN1LMNAKMT2AALDH1A1 | |
| SCHEMBL25179548 | 0.79 | CYP1A2 (0.34) | KMT2AFOLH1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143815-A1 | GROWTH HORMONE CONJUGATES | NOVO NORDISK HEALTH CARE AG (CH) | 2013-06-06 | — | — | US | disclosed |
| EP-2595661-A1 | GROWTH HORMONE CONJUGATES | Novo Nordisk Health Care AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010516-A1 | GROWTH HORMONE CONJUGATES | NOVO NORDISK HEALTH CARE AG (CH) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143815-A1 | GROWTH HORMONE CONJUGATES | GHRHR, GHSR, GHITM | KIF11 545/4885MEN1 389/4885LMNA 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.